[go: up one dir, main page]

BRPI0506630A - composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada - Google Patents

composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada

Info

Publication number
BRPI0506630A
BRPI0506630A BRPI0506630-1A BRPI0506630A BRPI0506630A BR PI0506630 A BRPI0506630 A BR PI0506630A BR PI0506630 A BRPI0506630 A BR PI0506630A BR PI0506630 A BRPI0506630 A BR PI0506630A
Authority
BR
Brazil
Prior art keywords
controlled release
administering
transmucosal
aqueous drug
release composition
Prior art date
Application number
BRPI0506630-1A
Other languages
English (en)
Inventor
Michael Moshman
Fred Mermelstein
Original Assignee
Innovative Drug Delivery Syste
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovative Drug Delivery Syste filed Critical Innovative Drug Delivery Syste
Publication of BRPI0506630A publication Critical patent/BRPI0506630A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçãO DE LIBERAçãO CONTROLADA E MéTODO PARA ADMINISTRAR UM MEDICAMENTO AQUOSO TRANSMUCOSAL DE LIBERAçãO CONTROLADA. A presente invenção refere-se à formulações trasmucosal de liberação controlada que mediam a absorção e a métodos de uso, compreendendo um agente farmaceuticamente ativo, preferivelmente, morfina, e um polímero solúvel em água, quitosano, e, preferivelmente, mais um antioxidante, um ou mais agentes microbianos, e água.
BRPI0506630-1A 2004-02-10 2005-02-09 composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada BRPI0506630A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/776,333 US20050175679A1 (en) 2004-02-10 2004-02-10 Controlled release formulations
PCT/US2005/004163 WO2005077346A1 (en) 2004-02-10 2005-02-09 Controlled release formulations

Publications (1)

Publication Number Publication Date
BRPI0506630A true BRPI0506630A (pt) 2007-05-08

Family

ID=34827359

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506630-1A BRPI0506630A (pt) 2004-02-10 2005-02-09 composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada

Country Status (10)

Country Link
US (2) US20050175679A1 (pt)
EP (1) EP1720532A1 (pt)
JP (1) JP2007522223A (pt)
KR (1) KR20060135769A (pt)
AU (1) AU2005212355B2 (pt)
BR (1) BRPI0506630A (pt)
CA (1) CA2555882A1 (pt)
IL (1) IL177328A0 (pt)
MX (1) MXPA06009094A (pt)
WO (1) WO2005077346A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100766820B1 (ko) 2006-01-23 2007-10-17 광주과학기술원 단백질 또는 펩타이드의 경점막 운반 시스템
JP2009508852A (ja) * 2006-01-23 2009-03-05 クワンジュ インスティチュート オブ サイエンス アンド テクノロジー 薬理活性物質と粘膜粘着性高分子とが共有結合されたコンジュゲート及びこれを用いた薬理活性物質の経粘膜運搬方法
US20080182819A1 (en) * 2007-01-29 2008-07-31 Act Iii Licensing, Llc Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
JP5258315B2 (ja) * 2007-05-25 2013-08-07 ロート製薬株式会社 フルニソリド含有粘膜適用組成物
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
EP2747561B1 (en) * 2011-08-25 2018-05-09 Evoke Pharma, Inc. Treatment of symptoms associated with female gastroparesis
US11517545B2 (en) 2016-12-15 2022-12-06 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
JP7217071B2 (ja) * 2019-09-30 2023-02-02 エルジー・ケム・リミテッド 高吸水性樹脂およびその製造方法
EP4230206A1 (en) * 2020-10-15 2023-08-23 Pharmbiotest Poland SP.ZO.O. Pharmaceutical composition based on nalbuphine and/or its salts for nasal administration

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5026825A (en) * 1988-09-08 1991-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Intranasal calcitonin formulations
US5478565A (en) * 1990-03-27 1995-12-26 Warner-Lambert Company Treatment of sinus headache
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5508282C1 (en) * 1993-05-17 2001-01-23 Tulin Silver Jeffrey Composition and method for treating acute or chronic rhinosinusitis
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
ATE180971T1 (de) * 1994-03-30 1999-06-15 Gs Dev Ab Verwendung von fettsäureester als bioklebstoffe
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
GB9605867D0 (en) * 1996-03-20 1996-05-22 Svedman Paul Transdermal device
GB9700624D0 (en) * 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
AU2879100A (en) * 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
EE200100677A (et) * 1999-06-16 2003-02-17 Nastech Pharmaceutical Co., Inc. Morfiini sisaldav farmatseutiline preparaat ninasiseseks manustamiseks ning meetod valuvaigistava või tuimastava reaktsiooni esilekutsumiseks imetajal
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
AU2001262992A1 (en) * 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
ITMI20010571A1 (it) * 2001-03-19 2002-09-19 Grisotech S A Vaccini assorbibili per via trans-mucosale

Also Published As

Publication number Publication date
EP1720532A1 (en) 2006-11-15
US20050175679A1 (en) 2005-08-11
WO2005077346A1 (en) 2005-08-25
IL177328A0 (en) 2006-12-10
KR20060135769A (ko) 2006-12-29
AU2005212355B2 (en) 2010-06-17
CA2555882A1 (en) 2005-08-25
AU2005212355A1 (en) 2005-08-25
US20080221144A1 (en) 2008-09-11
JP2007522223A (ja) 2007-08-09
MXPA06009094A (es) 2007-02-02

Similar Documents

Publication Publication Date Title
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
CL2003002277A1 (es) Composicion farmaceutica inyectable, de deposito de liberacion prolongada, que comprende un agente beneficioso disuelto o disperso en un gel constituido por un polimero bioerosionable y biocompatible; y un solvente.
AR054227A1 (es) Composicion de principios activos
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
BRPI0410503B8 (pt) composição tópica e uso da composição
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
CR10838A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
CR10726A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
TW200716208A (en) Modified and immediate release memantine bead formulation
CL2007003331A1 (es) Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente.
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
CR8428A (es) Agente endoparasiticidas para la administracion topica
BR0210489A (pt) Formulação farmacêutica oral, processo para preparar a mesma, uso da mesa, e método para preparar um distúrbio cardiovascular em um paciente
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada
GT200200115AA (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion .
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
BRPI0417350A2 (pt) composiÇço para a distribuiÇço nasal, uso de granisetron ou de um sal farmaceuticamente aceitÁvel do mesmo, e quitosana, um sal, um derivado ou sal de um derivado do mesmo, mÉtodos de administraÇço de granisetron ou de um sal farmaceuticamente aceitÁvel do mesmo, e de tratamento ou prevenÇço de nÁusea e/ou vâmito, e, dispositivo para a distribuiÇço da droga nasal ou um cartucho de dose
WO2008051527A3 (en) Sustained release of agents for localized pain management
WO2008049903A3 (en) Wide-area parasystemic treatment of skin related conditions
WO2009074853A3 (en) Ophthalmic composition comprising phenylephrine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]